الانتقال إلى المحتوى الرئيسي

اكتب مراجعة على PREreview

2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada

نُشر
الخادم
medRxiv
DOI
10.64898/2026.04.02.26350050

We evaluated 2024/25 KP.2 vaccine effectiveness (VE) against COVID-19 hospitalization among adults ≥60 years old eligible for publicly-funded vaccination during fall and/or spring campaigns in the province of Quebec, Canada. We included Quebec residents tested for COVID-19-compatible symptoms in an acute-care hospital between October 13, 2024 (epi-week 2024-42) and August 23, 2025 (2025-34), linking vaccine, hospital, chronic diseases and laboratory administrative records to assess VE through test-negative design. We compared the odds of being COVID-19 test-positive versus test-negative among vaccinated versus non-vaccinated participants, adjusting for sex, age, comorbidities, place of residence, and epidemiological week. Overall, 49,949 (43%) participants were vaccinated. Over an analysis period spanning up to ten months, including median time since vaccination of 16 weeks (interquartile range 9-24 weeks), VE was 34% overall, declining from 43% <8 weeks to negligible by the 32nd week post-vaccination. Findings confirm meaningful but short-lived COVID-19 vaccine protection against hospitalization in older adults.

Highlights

  • We estimate 2024/25 KP.2 vaccine effectiveness (VE) among adults aged ≥60 years

  • Vaccination reduced the COVID-19 hospitalization risk by one-third overall

  • Spring vaccine uptake was low, with shorter follow-up but VE like the fall analysis

  • VE waned from about 40% at <8 weeks to negligible at ≥32 weeks post-vaccination

  • COVID-19 VE against severe outcomes is meaningful but short-lived in older adults

يمكنك كتابة مراجعة PREreview لـ 2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada. مراجعة PREreview هي مراجعة لمسودة بحثية أولية، ويمكن أن تتراوح بين بضع جمل وتقرير مطوّل، على غرار تقرير مراجعة الأقران الذي تنظمه المجلات العلمية.

قبل أن تبدأ

سنطلب منك تسجيل الدخول باستخدام معرّف ORCID الخاص بك. إذا لم يكن لديك معرّف، يمكنك إنشاء واحد.

ما هو معرّف ORCID؟

يُعدّ معرّف ORCID معرّفًا فريدًا يميّزك عن كل من يحمل اسمًا مطابقًا أو مشابهًا لاسمك.

ابدأ الآن